Hemophilia A (Factor VIII Deficiency)

This Global website is not intended to represent or suggest that particular products are approved or authorized in any particular jurisdiction. You should not construe anything on this website as a promotion or solicitation for any product or service, or as suggesting that a product or service be used where it is not approved or authorized by applicable law and regulation in a particular country, territory, or jurisdiction. To learn which products are approved or authorized in particular countries, please consult the appropriate country-specific website.
Hemophilia A, also known as congenital factor VIII deficiency, is an X-chromosome-linked inherited bleeding disorder that causes a reduction in the amount or activity of factor VIII. Hemophilia A occurs in at least 1 in 10,000 people, almost always males, although it occasionally affects females (see Kristin's surprise diagnosis). Hemophilia A ranges in severity from mild surgery- or trauma-associated bleeding to spontaneous bleeding into muscles and joints. If these episodes are not treated properly and promptly, they can result in serious health consequences, including joint damage. 3, 5-6 

CSL Behring products used in the treatment of hemophilia A (congenital factor VIII deficiency) include:

LinkedIn Twitter Facebook Google+